Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases-C3 or C5 emerge together with CD14 as promising targets.

Barratt-Due, Andreas; Pischke, Søren Erik; Nilsson, Per H; Espevik, Terje; Mollnes, Tom Eirik

Barratt-Due, Andreas; Pischke, Søren Erik; Nilsson, Per H; Espevik, Terje; Mollnes, Tom Eirik.

Afiliação

Barratt-Due A; Department of Immunology, Oslo University Hospital, and K. G. Jebsen Inflammation Research Centre, University of Oslo, Oslo, Norway.
Pischke SE; Department of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway.
Nilsson PH; Department of Immunology, Oslo University Hospital, and K. G. Jebsen Inflammation Research Centre, University of Oslo, Oslo, Norway.
Espevik T; Department of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway.
Mollnes TE; Department of Immunology, Oslo University Hospital, and K. G. Jebsen Inflammation Research Centre, University of Oslo, Oslo, Norway.

J Leukoc Biol ; 101(1): 193-204, 2017 01.

Article em En | MEDLINE | ID: mdl-27581539

Assuntos

Complemento C3/antagonistas & inibidores; Complemento C5/antagonistas & inibidores; Inflamação/imunologia; Inflamação/terapia; Receptores de Lipopolissacarídeos/metabolismo; Terapia de Alvo Molecular; Receptores Toll-Like/metabolismo; Animais; Complemento C3/metabolismo; Complemento C5/metabolismo; Humanos

Palavras-chave

inflammation; innate immunity; therapy

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Complemento C3 / Complemento C5 / Receptores de Lipopolissacarídeos / Receptores Toll-Like / Terapia de Alvo Molecular / Inflamação Limite: Animals / Humans Idioma: En Revista: J Leukoc Biol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Noruega

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google